Connect with us

Hi, what are you looking for?

BioTechnology

Second Hospital Implants Aeson Bioprosthetic Artificial Heart

CARMAT has announced the second centre implanting its bioprosthetic artificial heart, Aeson, in the USA within the framework of the Early Feasibility Study (EFS).

Second Hospital Implants Aeson Bioprosthetic Artificial Heart

The implant procedure was performed by a team led by Mark S Slaughter, professor and chair of the Department of Cardiovascular and Thoracic Surgery at the University of Louisville (UofL) and UofL physician at Jewish Hospital, Louisville, USA. Jewish Hospital is the second US hospital to implant Aeson within the framework of the EFS. Three additional US centres are fully trained and are currently screening patients for the study.

In accordance with the study protocol approved by the US Food and Drug Administration (FDA), 10 transplant-eligible patients are expected to be enrolled in this trial. The primary study endpoint is patient survival at 180 days post-implant or a successful cardiac transplantation within 180 days post-implant. It is a staged study with a progress report of the first three patients after 60 days, before the enrollment of the next seven patients.

Slaughter, principal investigator of the study, stated: “We are pleased to be part of the first US centres to investigate this new artificial heart technology. This clinical study will help us determine whether the device’s distinguishing features such as haemocompatibility and blood flow autoregulation are beneficial to critically ill patients suffering from biventricular heart failure who currently have very limited treatment options.”

Stéphane Piat, chief executive officer of CARMAT, concluded: “We are honoured that our device is implanted at UofL Health – Jewish Hospital and University of Louisville, which is recognised throughout the USA for its quality of care and cardiovascular research. I would like to congratulate the teams at the hospital, as well as our technical and medical staff, on this exceptional milestone for both patients and our company.”

 

Seen on Cardiovascular News: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Artificial Intelligence

The agency says stakeholders can use the principles to tailor and adopt good practices from other sectors to be used in the health tech...

Artificial Intelligence

The platform is ultimately meant to help accelerate clinical trials and increase the probability of success of future therapies for Parkinson’s, Alzheimer’s, Multiple Sclerosis,...

Diagnostics

An Edinburgh researcher working on new therapies for difficult-to-treat cancers has become one of the first recipients of $20m worth of funding from an...

Digital Health

A freelance scientist from online platform Kolabtree has supported medical start-up Aires Medical with the development of a new oxygen concentrator.

You May Also Like

Artificial Intelligence

Digital Solutions In Healthcare Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm....

COVID-19

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Artificial Intelligence

Joe Mullings discusses the Microbot – Liberty robotic platform with Harel Gadot and how a new category of surgical robotics creates a new entry...

Digital Health

Software as a Medical Device (SaMD) is driving innovation in the HealthTech space and is more popular than ever — completely upending the way...